@misc{10481/92554,
year = {2024},
url = {https://hdl.handle.net/10481/92554},
abstract = {Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognosis and higher mortality among most
cancers. The diagnosis of PDA is frequently delayed due to a lack of specific biomarkers, and the efficacy of
current chemotherapeutic drugs is limited. Moreover, chemotherapy is generally applied in advanced stages,
where metastatic spread has already occurred. Nanotechnologybased systems are allowing to advance in the
diagnosis and treatment of PDA. New nanoformulations have shown to improve the activity of conventional
chemotherapeutic agents, such as gemcitabine, and new antitumor drugs, protecting them from degradation,
improving their selectivity, solubility and bioavailability, and reducing their side effects. Moreover, the design of
nanocarriers represents a new way to overcome drug resistance, which requires a comprehensive understanding
of the tumor microenvironment of PDA. This article reviews the current perspectives, based on nanomedicine,
to address the limitations of pancreatic cancer treatment, and the futures lines of research to progress in the
control of this disease},
publisher = {Bentham Science},
keywords = {Pancreatic ductal adenocarcinoma},
keywords = {Chemotherapeutic drugs},
keywords = {Nanoparticles},
title = {Nanomedicine in Pancreatic Cancer: A New Hope for Treatment},
doi = {10.2174/1389450121666200703195229},
author = {Redruello Guerrero, Pablo and Perazzoli, Gloria and Cepero, Ana and Quiñonero Muñoz, Francisco José and Mesas Hernández, Cristina and Doello, Kevin and Láinez Ramos-Bossini, Antonio Jesús and Rivera Izquierdo, Mario and Melguizo Alonso, Consolación and Prados Salazar, José Carlos},
}